Aimmune Therapeutics (Aimmune Therapeutics) Inventory Turnover : 1.00 (As of Jun. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Aimmune Therapeutics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Aimmune Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2020 was $4.85 Mil. Aimmune Therapeutics's Average Total Inventories for the quarter that ended in Jun. 2020 was $4.86 Mil. Aimmune Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2020 was 1.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Aimmune Therapeutics's Days Inventory for the three months ended in Jun. 2020 was 91.46.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Aimmune Therapeutics Inventory Turnover Historical Data

The historical data trend for Aimmune Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aimmune Therapeutics Inventory Turnover Chart

Aimmune Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Inventory Turnover

Get a 7-Day Free Trial

Aimmune Therapeutics Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Inventory Turnover	Get a 7-Day Free Trial															-	-	-	0.06	1.00

Aimmune Therapeutics Inventory Turnover Calculation

Aimmune Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2019 is calculated as

	Inventory Turnover (A: Dec. 2019 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2019 )	/ (	(Total Inventories (A: Dec. 2018 )	+	Total Inventories (A: Dec. 2019 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Aimmune Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2020 is calculated as

	Inventory Turnover (Q: Jun. 2020 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Jun. 2020 )	/ (	(Total Inventories (Q: Mar. 2020 )	+	Total Inventories (Q: Jun. 2020 ))	/	count )
=	4.85	/ (	(4.076	+	5.646)	/	2 )
=	4.85	/	4.861
=	1.00

Aimmune Therapeutics (NAS:AIMT) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Aimmune Therapeutics's Days Inventory for the three months ended in Jun. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2020 )	/	Cost of Goods Sold (Q: Jun. 2020 )	*	Days in Period
	=	4.861	/	4.85	*	365 / 4
	=	91.46

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Aimmune Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2020 )	/	Revenue (Q: Jun. 2020 )
	=	4.861	/	0
	=

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Aimmune Therapeutics Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Aimmune Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Aimmune Therapeutics (Aimmune Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aimmune Therapeutics Inc (NAS:AIMT) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 300, Brisbane, CA, USA, 94005

Website

https://www.aimmune.com

Aimmune Therapeutics Inc is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Executives

Gregory Behar	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Societe Des Produits Nestle S.a.	10 percent owner	AVENUE NESTLE 55, VEVEY V8 CH-1800
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Andrew Oxtoby	officer: Chief Commercial Officer	8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Dallas Jayson Donald Alexander	director, officer: President and CEO	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Stacey Denenberg Seltzer	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Brett K Haumann	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Douglas T. Sheehy	officer: See Remarks	C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005-1884
Mark T Iwicki	director	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Patrick G Enright	director	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Mark Mcdade	director	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Adelman Daniel C Md	officer: Chief Medical Officer	23 WOODLEAF AVENUE, REDWOOD CITY CA 94061
Eric Bjerkholt	officer: Chief Financial Officer	132 PURDURE AVENUE, KENGSINGTON CA 94708
Sa Nestle	10 percent owner	AVE NESTLE 55, CH-1800, VEVEY V8
Mary M. Rozenman	officer: See Remarks	AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005